Jason Sheltzer

Check out our new study in @ScienceMagazine, where we take on a 100-year-old debate: what’s the role of aneuploidy in cancer?

We discovered that genetically removing extra chromosomes blocks cancer growth - a phenomenon we call “aneuploidy addiction”. science.org/doi/10.1126/sc…

I’m thrilled to share our new preprint, in which we describe what I think may be the best way to selectively target aneuploid cancers while sparing normal euploid tissue.

Put up some Halloween decorations last night, woke up to 16 term sheets in my mailbox.

This week, $ACRV announced that they’re preparing an IND filing for a CDK11 inhibitor. Several other companies have CDK11 programs.

I very much want CDK11 inhibitors to succeed in the clinic, though our paper suggests that on-target tox will limit their therapeutic potential.

Pleased to share my lab’s new manuscript integrating genomics, drug development, cell biology, and mouse modeling to comprehensively evaluate the cyclin-dependent kinase CDK11 as a drug target in cancer.